Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vermillion Announces Closing of Equity Financing

Published: Thursday, May 16, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
Company to increase the number of directors of the Company from six to eight persons.

Vermillion, Inc. has announced that it has closed a previously announced private placement through which 8.0 million shares of the Company's common stock were purchased by Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and other investors.

Gross proceeds of the private placement totaled approximately $13.2 million, with net proceeds totaling approximately $11.8 million after anticipated offering expenses. Emerging Growth Equities, Ltd. advised the company on this transaction.

As previously announced, Vermillion also issued warrants exercisable for 12.5 million shares of the Company's common stock at $1.46 per share as part of the close.

If and when the warrants are exercised, Vermillion will realize an additional $18.3 million in proceeds, bringing the total investment to $31.5 million before transaction costs.

Proceeds from this transaction will be used to increase test sales and improve reimbursement for OVA1, expand the commercial opportunity into new markets, and advance one or more next-generation ovarian cancer diagnostic tests.

Vermillion has also announced that its Board of Directors has approved an amendment to the Company's bylaws to increase the number of directors of the Company from six to eight persons, creating two new Class III director positions. This increase was required under the terms of the private placement.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Friday, March 21, 2014
Vermillion Reports Fourth Quarter and Full Year 2013 Results
Company will next pursue a national price for its OVA1 test in 2014.
Saturday, March 08, 2014
Vermillion to Present at the 26th Annual ROTH Conference
Company to present at the conference on March 11, 2014.
Thursday, March 06, 2014
Vermillion to Present at Leerink Global Healthcare Conference
Conference to be held at the Waldorf Astoria Hotel from February 12-13, 2014.
Tuesday, February 04, 2014
Vermillion Completes $17.6 Million Warrant Exercise
Proceeds from the warrant exercise will be used to increase test sales for OVA1.
Friday, December 20, 2013
Vermillion Reports Results of 2013 Annual Meeting
Company has approved the reappointment of Peter S. Roddy.
Friday, December 20, 2013
Vermillion Appoints SVP of Sales and Marketing and Chief Commercial Officer
Appointment of Marian E. Sacco as senior vice president of sales and marketing.
Friday, December 20, 2013
Vermillion Board of Directors Elects James T. LaFrance as Chairman
LaFrance has been appointed a member of Company’s board on December 12, 2013.
Monday, December 16, 2013
Vermillion Reports Third Quarter 2013 Results
Company reports Q3 2013 financial results and key developments.
Friday, November 15, 2013
American Journal of Obstetrics & Gynecology Publishes New Clinical Study of OVA1 Test
Significantly superior early-stage sensitivity shown versus CA125, modified ACOG guidelines or overall clinical assessment in premenopausal and postmenopausal women planning surgery.
Thursday, November 14, 2013
Vermillion Appoints Dr. Eric Varma to its Board of Directors
Dr. Varma is currently a partner at Oracle Investment Management.
Tuesday, September 17, 2013
Vermillion's OVA1 Receives New Statement by SGO
OVA1® has received new statement on clinical validation and medical use.
Tuesday, July 16, 2013
Vermillion Appoints President and Chief Executive Officer
Appointment of Thomas McLain effective March 18, 2013.
Thursday, July 04, 2013
Vermillion Appoints Bruce A. Huebner to Chairman of the Board
Shareholders to vote on approval of expanded stock incentive plan at upcoming annual meeting.
Friday, June 28, 2013
Vermillion Supports First World Ovarian Cancer Day
Vermillion offers women new hope with OVA1, a FDA-cleared test designed to aid in the prediction of malignancy prior to surgery on an ovarian mass.
Thursday, May 16, 2013
Scientific News
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Diagnosing Bacterial Infections in Blood Samples
Researchers have diagnosed a bacterial infection from a blood sample in infants.
Neurodvelopmental Disorder Cause Linked to SON Gene
A genetic link has been discovered for a previously unxplained neurodevelopmental disorder.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Misdiagnosis in HCM Tests
Genetic tests for potentially fatal heart anomaly can misdiagnose condition in black Americans.
Computers Better Predict Lung Cancer Type, Severity
Study shows automating the analysis of cancer tissue samples increases the accuracy of tumor classification and patient prognoses.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Automating Genetic Analysis
Researchers are looking to have computers help perform genetic analysis when scientists study a patient's genome to diagnose a disease.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!